Poster Presentation The 13th International Congress of the Immunology of Diabetes Society 2013

Novel Enzyme-Linked Immunosorbent Assay for Bivalent ZnT8 Autoantibodies (#90)

Eiji Kawasaki 1 , Megumi Tanaka 2 , Masaki Miwa 1 , Norio Abiru 1 , Atsushi Kawakami 1
  1. Nagasaki University Hospital, Nagasaki, Japan
  2. Cosmic Corporation, Tokyo, Japan

Autoantibodies to zinc transporter 8 (ZnT8A) is a powerful diagnostic or predictive marker in type 1 diabetes. However, the widely used current ZnT8A radioligand binding assay (RBA) has proved to be difficult for many laboratories to implement. The aim of this study was the development and characterization of the performance of a novel fluid phase ZnT8A enzyme-linked immunosorbent assay (ELISA) in relation to standard radioligand binding assay (RBA) in type 1 diabetes. Sera from 114 patients with type 1 diabetes and 140 blinded Islet Autoantibody Standardization Program (IASP2012) samples were studied. The sensitivity of ELISA-ZnT8A is equivalent or even higher than conventional RBA with similar specificity. Furthermore, the mean SD score using this ELISA was significantly higher than that obtained with RBA (P<0.0001). Multiple logistic regression analysis revealed that ELISA-ZnT8A positivity was associated with younger age of onset (≤ 20 years; OR 15.91, P=0.0002), acute-onset form of type 1 diabetes (OR 3.38, P=0.019), and the presence of IA-2 autoantibodies (OR 3.75, P=0.014). Furthermore, the levels of ELISA-ZnT8A were associated with the reactivity to ZnT8-325Arg, but not ZnT8-325Trp. We conclude that this nonradioactive bivalent ZnT8A assay has high performance and should facilitate large-scale autoantibody screening. Moreover, these results suggest that the humoral autoimmunity against ZnT8 is related to a high risk of faster development of type 1 diabetes and the ZnT8A levels are associated with the known aa325 variants